Abstract
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder characterized by epidermal barrier dysfunction, immune dysregulation, and intense pruritus. Although existing treatments, including topical corticosteroids, calcineurin inhibitors, and biologic agents, are effective for many patients, concerns regarding long‐term safety, cost, and incomplete disease control have driven interest in nonimmunosuppressive and complementary therapeutic strategies. L‐histidine is an essential dietary amino acid that has emerged as a potential biologic modulator in AD due to its central role in filaggrin metabolism and natural moisturizing factor (NMF) production. This narrative review synthesizes the current mechanistic, preclinical, and clinical evidence evaluating L‐histidine as a therapeutic or adjunctive intervention in AD. L‐histidine supports epidermal hydration, pH homeostasis, and barrier integrity through its role as a precursor of filaggrin‐derived NMF components. In vitro and skin‐equivalent models demonstrate that L‐histidine enhances filaggrin processing and improves functional barrier properties. Importantly, mechanistic studies indicate that histidine supplementation does not promote pathological histamine production, alleviating concerns regarding histamine‐mediated disease exacerbation. Clinical evidence, though limited to small exploratory trials and case reports, shows reductions in disease severity and pruritus in both pediatric and adult patients receiving oral L‐histidine supplementation. However, these findings should be regarded as preliminary rather than conclusive. The magnitude of improvement reported in these small trials has been described by the authors as similar to SCORAD reductions historically reported for mid‐potency topical corticosteroids. However, this is a benchmark comparison against external historical literature, not a head‐to‐head assessment. Since no head‐to‐head trial has directly compared L‐histidine with topical corticosteroids, its efficacy should not be considered equivalent or directly comparable to that of topical corticosteroids. Oral L‐histidine has demonstrated a favorable safety and tolerability profile to date, with no serious adverse events reported. L‐histidine is a low‐cost, well‐tolerated, barrier‐targeted adjunct with potential utility in AD management. Larger, long‐term randomized controlled trials incorporating genetic stratification and combination therapy designs are warranted to better define its optimal role in clinical practice.

This publication has 39 references indexed in Scilit: